Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
BMC Urology
Published in: BMC Urology 1/2018

Open Access 01-12-2018 | Research article

Anticholinergic burden and comorbidities in patients attending treatment with trospium chloride for overactive bladder in a real-life setting: results of a prospective non-interventional study

Authors: A. Ivchenko, R.-H. Bödeker, C. Neumeister, A. Wiedemann

Published in: BMC Urology | Issue 1/2018

Login to get access

Abstract

Background

Elderly people are representative for the patients most likely to be treated with anticholinergics for overactive bladder (OAB). They often receive further drugs with anticholinergic properties for concomitant conditions. This increases the risk for side effects, including central nervous system disorders. Data on comorbidities and baseline anticholinergic burden of OAB patients seen in urological practice is scarce. Therefore, we included an epidemiological survey on these issues in our study which assessed the effectiveness and tolerability of trospium chloride (TC) in established dosages under routine conditions.

Methods

Outpatients (≥ 65 years of age), for whom treatment with TC was indicated, were eligible to participate in this non-interventional, prospective study performed in 162 urological practices in Germany. Epidemiological questions were evaluated by the Anticholinergic Burden (ACB) scale and the Cumulative Illness Rating Scale for Geriatrics (CIRS-G) at baseline. Efficacy was assessed by changes in symptom-related variables of OAB after treatment. Dosage regimen, duration of treatment, adverse events, withdrawals, and ease of subdivision of the prescribed SNAP-TAB tablet were documented. Patients and physicians rated efficacy and tolerability of treatment. Statistics were descriptive.

Results

Four hundred fourty-five out of 986 (47.54%) patients in the epidemiological population had a baseline ACB scale score > 0, 100 (24.72%) of whom a score ≥ 3. The median CIRS-G comorbidity index score for all patients was 5. 78.55% (608/774) of patients in the efficacy population received a daily dose of 45 mg TC. 60.03% (365/608) of them took this dose by dividing the SNAP-TAB tablet in three equal parts. Before-after-comparisons of the core symptoms of OAB showed clear improvements. An influence of the dosage scheme (1 × 45 mg TC/d vs 3 × 15 mg TC/d) on clinical outcome could not be observed. Most urologists and patients rated TC treatment as effective and well tolerated. 44 (4.37%) out of 1007 patients in the safety collective ended their treatment prematurely, while 75 patients (7.45%) experienced adverse events.

Conclusions

Anticholinergic burden and comorbidities in elderly OAB patients are frequent. The acceptance of the SNAP-TAB tablet, which facilitates flexible dosing with TC, was high, which is supportive in ensuring adherence in therapy.

Trial registration

This non-interventional study was registered on October 29, 2014 with the number DRKS00007109 at the German Register of Clinical Studies (DRKS).
Footnotes
1
Trademark: Spasmex® 45 mg film-coated immediate-release tablets (Dr. R. Pfleger GmbH, Bamberg, Germany)
 
Literature
1.
Zellner M, Madersbacher H, Palmtag H, et al, and the P195 Study Group. Trospium chloride and oxybutynin hydrochloride in a German study of adults with urinary urge incontinence: results of a 12-week, multicenter, randomized, double-blind, parallel-group, flexible-dose noninferiority trial. Clin Ther 2009; 31: 2519–2539.
2.
Ulshöfer B, Bihr AM, Bödeker RH, et al. Randomised, double-blind, placebo-controlled study on the efficacy and tolerance of trospium chloride in patients with motor urge incontinence. Clin Drug Invest. 2001;21(8):563–9.CrossRef
3.
Cardozo L, Chapple CR, Toozs-Hobson P, et al. Efficacy of trospium chloride in patients with detrusor instability: a placebo-controlled, randomised, double-blind, multicentre clinical trial. BJU. 2000;85:659–64.CrossRef
4.
Alloussi S, Laval KU, Eckert R, et al. Trospium chloride (Spasmo-lyt®) in patients with motor urge syndrome (detrusor instability): a double-blind, randomised, multicentre, placebo-controlled study. J. Clin Res. 1998;1:439–51.
5.
Jünemann KP, Füsgen I, Svetlana T. Trospium chloride 40 mg – a placebo-controlled, randomised, double-blind clinical trial on the efficacy and tolerability for 3 weeks in patients with urge-syndrome. Eur Urol. 2000;37:84.
6.
Jünemann KP, Füsgen I. Placebo-controlled, randomised, double-blind, multicentre clinical trial on the efficacy and tolerability of 1x40 mg and 2x40 mg trospium chloride (Spasmo-lyt®) daily for 3 weeks in patients with urge-syndrome. Neurourol Urodynam. 1999;18:375–6.
7.
Bödeker RH, Madersbacher H, Neumeister C, Zellner M. Dose escalation improves therapeutic outcome: post hoc analysis of data from a 12-week, multicentre, double-blind, parallel-group trial of trospium chloride in patients with urinary urge incontinence. BMC Urol. 2010;10:15.CrossRefPubMedPubMedCentral
8.
9.
Wiedemann A, Kusche W, Neumeister C. Flexible dosing of trospium chloride for the treatment of OAB – results of a non-interventional study in 4,092 patients. The Open Clinical Trials Journal. 2011;3:1–5.CrossRef
10.
11.
Wiedemann A, Füsgen I. Harninkontinenz bei Älteren. © pharma-aktuell Verlagsgruppe GmbH/Geriatrie-Report, Varel. Bamberg, Germany; 2017. (German)
12.
Wagg A. The cognitive burden of anticholinergics in the elderly – implications for the treatment of overactive bladder. Eur Urol Rev. 2012;7(1):42–9.
13.
Lenherr SM, Cox L. Cognitive effects of anticholinergics in the geriatric patient population: safety and treatment considerations. Cur Bladder Dysfunct Rep. 2017;12:104–11.CrossRef
14.
Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia. A prospective cohort study. JAMA Intern Med. 2015;175(3):401–7.CrossRefPubMedPubMedCentral
15.
Salahudeen MS, Duffull SB, Nishtala PS. Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review. BMC Geriatr. 2015;15:31.CrossRefPubMedPubMedCentral
16.
Marcum ZA, Wirtz HS, Pettinger M, et al. Anticholinergic medication use and falls in postmenopausal women: findings from the women’s health initiative cohort study. BMC Geriatr. 2016;16:76.CrossRefPubMedPubMedCentral
17.
18.
Fox C, Richardson K, Maidment ID, et al. Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study. J Am Geriatr Soc. 2011;59:1477–83.CrossRefPubMed
19.
Boustani M, Cambell N, Munger S, et al. Impact of anticholinergics on the aging brain: a review and practical application. Aging Health. 2008;4(3):311–20.CrossRef
20.
Campbell N, Boustani M, Limbil T, et al. The cognitive impact of anticholinergics: a clinical review. Clin Interv Aging. 2009;4:225–33.PubMedPubMedCentral
21.
Pasina L, Djade CD, Lucca U, et al. Association of anticholinergic burden with cognitive and functional status in a cohort of hospitalized elderly: comparison of the anticholinergic cognitive burden scale and anticholinergic risk scale. Drugs Aging. 2013;30:103–12.CrossRefPubMed
22.
23.
Luscombe FA. Socioeconomic burden of urinary incontinence with focus on overactive bladder and tolterodine treatment. Rev Contemp Pharmacother. 2000;11:43–62.
24.
Tubaro A. Defining overactive bladder: epidemiology and burden of disease. Urology. 2004;64(Suppl 6A):2–6.CrossRefPubMed
25.
Lua LL, Pathak P, Dandolu V. Comparing anticholinergic persistence and adherence profiles in overactive bladder patients based on gender, obesity, and major anticholinergic agents. Neurourol Urodyn. 2017;36:2123–31.CrossRefPubMed
26.
Coyne KS, Wein A, Nicholson S, et al. Comorbidities and personal burden of urgency urinary incontinence: a systematic review. Int J Clin Pract. 2013;67(10):1015–33.CrossRefPubMed
27.
Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50:1306–15.CrossRef
28.
Stickley A, Santini ZI, Koyanagi A. Urinary incontinence, mental health and loneliness among community-dwelling older adults in Ireland. BMC Urol. 2017;17:29.CrossRefPubMedPubMedCentral
29.
Lai HH, Shen B, Rawal A, Vetter J. The relationship between depression and overactive bladder/urinary incontinence symptoms in the clinical OAB population. BMC Urol. 2016;16:60.CrossRefPubMedPubMedCentral
30.
Felde G, Ebbesen MH, Hunskaar S. Anxiety and depression associated with urinary incontinence. A 10-year follow-up study from the Norwegian HUNT study (EPINCONT). Neurourol Urodynam. 2017;36:322–8.CrossRef
31.
32.
Andersson KE, Chapple CR, Cardozo L, et al. Pharmacological treatment of urinary incontinence. In: Abrams P, Cardozo L, Khoury S, Wein A, editors. Incontinence. 4th international consultation on incontinence. UK, Plymouth: Plymouth, Plymbridge Contributors Ltd; 2009. p. 631–700.
33.
Lechevallier-Michel N, Molimard M, Dartigues JF, et al. Drugs with anticholinergic properties and cognitive performance in the elderly: results from the PAQUID study. Br J Clin Pharmacol. 2004;59(2):143–51.CrossRef
34.
Erdo F, Denes L, de Lange E. Age-associated physiological and pathological changes at the blood-brain-barrier: a review. J Cereb Blood Flow Metab. 2017;37(I):4–24.CrossRefPubMed
35.
Gerretsen P, Pollock BG. Cognitive risks of anticholinergics in the elderly. Aging Health. 2013;9(2):159–66.CrossRef
36.
Ruxton K, Woodman RJ, Mangoni AA. Drugs with anticholinergic effects and cognitive impairment, falls and all-cause mortality in older adults: a systematic review and meta-analysis. Br J Clin Pharmacol. 2015;80(2):209–20.CrossRefPubMedPubMedCentral
37.
38.
Hoffmann W, Latza U, Terschüren C. Leitlinien und Empfehlungen zur Sicherung von Guter Epidemiologischer Praxis (GEP). German: Deutsche Gesellschaft für Epidemiologie (DGEpi); 2008.
39.
AWMF. Guideline No. 084/001. Harninkontinenz. German: Leitlinien der Deutschen Gesellschaft für Geriatrie; 2010.
40.
Summary of Product Characteristics (SmPC). Spasmex® 45 mg film-coated tablets. Dr. R. Pfleger GmbH. Version 09/2013. www.​fachinfo.​de.
41.
Van Santen E, Barends DM, Frijlink HW. Breaking of scored tablets: a review. Eur J Pharma Biopharm. 2002;53:139–45.CrossRef
42.
Wening K, Breitkreutz J. Oral drug delivery in personalized medicine: unmet needs and novel approaches. Int J Pharm. 2011;404:1–9.CrossRefPubMed
43.
Kolanowski A, Fick DM, Campbell J, et al. A preliminary study of anticholinergic burden and relationship to quality of life indicator, engagement in activities, in nursing home residents with dementia. J Am Med Dir Assoc. 2009;10(4):252–7.CrossRefPubMedPubMedCentral
44.
Lertxundi U, Domingo-Echaburu S, Hernandez R, et al. Expert-based drug list to measure anticholinergic burden: similar names, different results. Psychogeriatrics. 2013;13:17–24.CrossRefPubMed
45.
Hock G, Nosper M. Manual CIRS-G. Cumulative Illness Rating Scale. Skala zur kumulierten Bewertung von Erkrankungen. V 2.1, MDK Rheinland-Pfalz 2003. English original paper: a manual of guidelines for scoring the cumulative illness rating scale (CIRS-G), by Miller MD & Towers A. Department of Geriatric Psychiatry, University of Pittsburgh, USA, 1991.
46.
Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale, NJ: L. Erlbaum Associates; 1988.
47.
Ellis PD. The essential guide to effect sizes: statistical power, meta-analysis, and the interpretation of research results. Cambridge: Cambridge University Press; 2010.
48.
Irwin DE, Kopp ZS, Agatep B, et al. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int. 2011;108:1132–9.CrossRefPubMed
49.
Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they manages? A population-based prevalence study. BJU Int. 2001;87:760–6.CrossRefPubMed
50.
51.
Koyama A, Steinman M, Ensrud K, et al. Long-term cognitive and functional effects of potentially inappropriate medications in older women. J Gerontol A Biol Sci Med Sci. 2014;69(4):423–9.CrossRefPubMed
52.
Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012;380:37–43.CrossRef
53.
Laux G, Kuehlein T, Rosemann T, Szecsenyi J. Co- and multimorbidity patterns in primary care based on episodes of care: results from the German CONTENT project. BMC Health Serv Res. 2008;8:14.CrossRefPubMedPubMedCentral
54.
Salvi F, Miller MD, Grilli A, et al. A manual of guidelines to score the modified cumulative illness rating scale and its validation in acute hospitalized elderly patients. J Am Geriatr Soc. 2008;56:1926–31.CrossRefPubMed
55.
Miller MD, Paradis CF, Houck PR, et al. Rating chronic medical illness burden in geropsychiatric practice and research: application of the cumulative illness rating scale. Psychiatry Res. 1992;41:237–48.CrossRefPubMed
56.
King LA, Priest KC, Nutt J, et al. Comorbidity and functional mobility in persons with Parkinson’s disease. Arch Phys Med Rehabil. 2014;95(11):2152–7.CrossRefPubMedPubMedCentral
57.
Cramer P. The management of fit, unfit, and high-risk CLL patients. New Evid Oncol. 2014;25:52–7.
58.
Ancelin ML, Artero S, Portet F, et al. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. BMJ. 2006;332:455–9.CrossRefPubMedPubMedCentral
59.
Turnheim K. When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly. Exp Gerontol. 2003;38:843–53.CrossRef
60.
61.
Chuang Y-F, Elango P, Gonzalez CE, Thambisetty M. Midlife anticholinergic drug use, risk of Alzheimer’s disease, and brain atrophy in community-dwelling older adults. Alzheimers Dement Transl Res Clin Intervent. 2017;3:471–9.CrossRef
62.
Geyer J, Gavrilova O, Petzinger E. The role of P-glycoprotein in limiting brain penetration of the peripherally acting anticholinergic overactive bladder drug trospium chloride. Drug Metab Dispos. 2009;37:1371–4.CrossRefPubMed
63.
64.
65.
Geller EJ, Dumond JB, Bowling JM, et al. Effect of trospium chloride on cognitive function in women aged 50 or older: a randomized trial. Female Pelvic Med Reconstr Surg. 2017;23(2):118–23.CrossRefPubMed
66.
Pietzko A, Dimpfel W, Schwantes U, Topfmeier P. Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers. Eur J Clin Pharmacol. 1994;47:337–43.CrossRefPubMed
67.
Todorova A, Vonderheid-Guth B, Dimpfel W. Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol. 2001;41:636–44.CrossRefPubMed
68.
Diefenbach K, Arold G, Wollny A, et al. Effects on sleep of anticholinergics used for overactive bladder treatment in healthy volunteers aged ≥ 50 years. BJU Int. 2005;95(3):346–9.CrossRefPubMed
69.
Diefenbach K, Donath F, Maurer A, et al. Randomised, double-blind study of the effects of oxybutynin, tolterodine, trospium chloride and placebo on sleep in healthy young volunteers. Clin Drug Invest. 2003;23(6):395–404.CrossRef
70.
Staskin D, Kay G, Goldman H, et al. Central nervous system penetration and effect on memory: comparison of trospium chloride and oxybutynin in patients with overactive bladder and age-associated memory impairment. Neurourol Urodynam. 2012; https://​doi.​org/​10.​1002/​nau.
71.
Staskin D, Kay G, Tannenbaum C, et al. Trospium chloride has no effect on memory testing and is assay undetectable in the central nervous system of older patients with overactive bladder. Int J Clin Pract. 2010;64(9):1294–300.CrossRefPubMed
72.
Staskin D, Kay G, Tannenbaum C, et al. Trospium chloride is undetectable in the older human central nervous system. J Am Geriatr Soc. 2010;58(8):1618–9.CrossRefPubMed
73.
Staskin DR, Harnett MD. Effect of trospium chloride on somnolence and sleepiness in patients with overactive bladder. Curr Urol Rep. 2004;5:423–6.CrossRefPubMed
74.
75.
Summary of Product Characteristics (SmPC) Spasmex® 45 mg film-coated tablets. Dr. R. Pfleger GmbH. 2017. http://​www.​fachinfo.​de; 014933.pdf. Accessed 11-16-2017.
76.
77.
Von Jeinsen BKJG, Sudhop T. A 1-year cross-sectional analysis of non-interventional post-marketing study protocols submitted to the German Federal Institute for Drugs and Medical Devices (BfArM). Eur J Clin Pharmacol. 2013;69:1453–66.CrossRefPubMedPubMedCentral
Metadata
Title
Anticholinergic burden and comorbidities in patients attending treatment with trospium chloride for overactive bladder in a real-life setting: results of a prospective non-interventional study
Authors
A. Ivchenko
R.-H. Bödeker
C. Neumeister
A. Wiedemann
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Urology / Issue 1/2018
Electronic ISSN: 1471-2490
DOI
https://doi.org/10.1186/s12894-018-0394-8

Other articles of this Issue 1/2018

BMC Urology 1/2018 Go to the issue

Research article

Surgical management of urolithiasis – a systematic analysis of available guidelines

Research article

Epidermal growth factor expression as a predictor of chemotherapeutic resistance in muscle-invasive bladder cancer

Research article

Progressive bladder remodeling due to bladder outlet obstruction: a systematic review of morphological and molecular evidences in humans

Research article

Changes in renal papillary density after hydration therapy in calcium stone formers

Research article

Effect of sample time on urinary lithogenic risk indexes in healthy and stone-forming adults and children

Technical advance

Minimally invasive surgical treatment on delayed uretero-vaginal fistula